SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
Abstract Background: Type 2 diabetes mellitus (T2DM) is a progressive chronic disease associated with severe microvascular and macrovascular complications. Our aim is to assess the real world effectiveness of SGT" inhibitors in achieving metabolic therapeutic goals. Methods: A retrospective, ob...
| Autores principales: | , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
2017
|
| Acceso en línea: | http://eprints.uanl.mx/17587/1/372.pdf |
| _version_ | 1824414944643252224 |
|---|---|
| author | Tamez Pérez, Héctor Eloy Delgadillo Esteban, Enrique Soni Duque, David Hernández Coria, Mayra Ivonne Tamez Peña, Alejandra Lorena |
| author_facet | Tamez Pérez, Héctor Eloy Delgadillo Esteban, Enrique Soni Duque, David Hernández Coria, Mayra Ivonne Tamez Peña, Alejandra Lorena |
| author_sort | Tamez Pérez, Héctor Eloy |
| collection | Repositorio Institucional |
| description | Abstract Background: Type 2 diabetes mellitus (T2DM) is a progressive chronic disease associated with severe microvascular and macrovascular complications. Our aim is to assess the real world effectiveness of SGT" inhibitors in achieving metabolic therapeutic goals. Methods: A retrospective, observational study. Inclusion criteria for patients were a previous diagnosis of type 2 diabetes mellitus, age > 18 years, patients receiving either dapagliflozin 10 mg and/or canagliflozin 300 mg. We excluded pregnant patients, patients with type 1 diabetes mellitus and acute metabolic complications of diabetes. Patients included in the analysis were enrolled in a health plan at least 6 months prior to the index date (baseline period) and in the 6 months following the index date (follow-up period). Achievement of glycated hemoglobin goals were established as <7%. Results: We screened 2870 Mexican patients; 288 (10.03% received SGLT2 inhibitors). Mean age for both groups of patients was 57.68±11.06 years. The dapagliflozin control rate was 19.56% and the canagliflozin control rate 18.96%. Monotherapy with SGLT2 inhibitors was used in 21 patients (6.25%). Overall HbA1c goals were met in 56 patients (19. 44%) with similar results with dapagliflozin or canagliflozin. The combination of SGLT2 inhibitors and sulfonylureas had the highest control rate (30.30%) compared to other regimens. Monotherapy was present in 6.25%. Insulin requirement was associated with poor control (2.8% vs. 18.05%, P<0.05, 95% CI [0.07, 0.84]). Combination therapy with DPP4 inhibitors was associated with better control (P<0.05, 95% CI, [1.10, 3.92]). Conclusion: No difference between the drugs was observed. Real-world effectiveness data of SGLT2 inhibitors show that the percentage of patients reaching metabolic goals is low. SLGT2 inhibitors were used more frequently as combined therapy. Keywords: Dapagliflozin, Canagliflozin, Diabetes Mellitus, Type 2, Effectiveness research, comparative, Hemoglobin A, Glycosylated |
| format | Article |
| id | eprints-17587 |
| institution | UANL |
| language | English |
| publishDate | 2017 |
| record_format | eprints |
| spelling | eprints-175872020-06-10T17:07:21Z http://eprints.uanl.mx/17587/ SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study Tamez Pérez, Héctor Eloy Delgadillo Esteban, Enrique Soni Duque, David Hernández Coria, Mayra Ivonne Tamez Peña, Alejandra Lorena Abstract Background: Type 2 diabetes mellitus (T2DM) is a progressive chronic disease associated with severe microvascular and macrovascular complications. Our aim is to assess the real world effectiveness of SGT" inhibitors in achieving metabolic therapeutic goals. Methods: A retrospective, observational study. Inclusion criteria for patients were a previous diagnosis of type 2 diabetes mellitus, age > 18 years, patients receiving either dapagliflozin 10 mg and/or canagliflozin 300 mg. We excluded pregnant patients, patients with type 1 diabetes mellitus and acute metabolic complications of diabetes. Patients included in the analysis were enrolled in a health plan at least 6 months prior to the index date (baseline period) and in the 6 months following the index date (follow-up period). Achievement of glycated hemoglobin goals were established as <7%. Results: We screened 2870 Mexican patients; 288 (10.03% received SGLT2 inhibitors). Mean age for both groups of patients was 57.68±11.06 years. The dapagliflozin control rate was 19.56% and the canagliflozin control rate 18.96%. Monotherapy with SGLT2 inhibitors was used in 21 patients (6.25%). Overall HbA1c goals were met in 56 patients (19. 44%) with similar results with dapagliflozin or canagliflozin. The combination of SGLT2 inhibitors and sulfonylureas had the highest control rate (30.30%) compared to other regimens. Monotherapy was present in 6.25%. Insulin requirement was associated with poor control (2.8% vs. 18.05%, P<0.05, 95% CI [0.07, 0.84]). Combination therapy with DPP4 inhibitors was associated with better control (P<0.05, 95% CI, [1.10, 3.92]). Conclusion: No difference between the drugs was observed. Real-world effectiveness data of SGLT2 inhibitors show that the percentage of patients reaching metabolic goals is low. SLGT2 inhibitors were used more frequently as combined therapy. Keywords: Dapagliflozin, Canagliflozin, Diabetes Mellitus, Type 2, Effectiveness research, comparative, Hemoglobin A, Glycosylated 2017 Article PeerReviewed text en cc_by_nc_nd http://eprints.uanl.mx/17587/1/372.pdf http://eprints.uanl.mx/17587/1.haspreviewThumbnailVersion/372.pdf Tamez Pérez, Héctor Eloy y Delgadillo Esteban, Enrique y Soni Duque, David y Hernández Coria, Mayra Ivonne y Tamez Peña, Alejandra Lorena (2017) SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study. Journal of Diabetes & Metabolic Disorders, 16 (1). pp. 1-5. ISSN 2251-6581 http://doi.org/10.1186/s40200-017-0308-4 doi:10.1186/s40200-017-0308-4 |
| spellingShingle | Tamez Pérez, Héctor Eloy Delgadillo Esteban, Enrique Soni Duque, David Hernández Coria, Mayra Ivonne Tamez Peña, Alejandra Lorena SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study |
| thumbnail | https://rediab.uanl.mx/themes/sandal5/images/online.png |
| title | SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study |
| title_full | SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study |
| title_fullStr | SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study |
| title_full_unstemmed | SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study |
| title_short | SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study |
| title_sort | sglt2 inhibitors as add on therapy in type 2 diabetes a real world study |
| url | http://eprints.uanl.mx/17587/1/372.pdf |
| work_keys_str_mv | AT tamezperezhectoreloy sglt2inhibitorsasaddontherapyintype2diabetesarealworldstudy AT delgadilloestebanenrique sglt2inhibitorsasaddontherapyintype2diabetesarealworldstudy AT soniduquedavid sglt2inhibitorsasaddontherapyintype2diabetesarealworldstudy AT hernandezcoriamayraivonne sglt2inhibitorsasaddontherapyintype2diabetesarealworldstudy AT tamezpenaalejandralorena sglt2inhibitorsasaddontherapyintype2diabetesarealworldstudy |